Welcome to our dedicated page for Kiniksa Pharmaceuticals International news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International stock.
Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET. A live webcast will be available via the Investors & Media section of the company's website, and a replay will be posted approximately 48 hours after the event. Telephone participants must register to receive dial-in details and a unique passcode.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported unaudited ARCALYST net product revenue of $677.5M in 2025, ~62% year-over-year growth, and expects 2026 ARCALYST revenue of $900M–$920M. Gross-to-net was 8.4% in 2025 vs 9.8% in 2024, reflecting Inflation Reduction Act impacts and fourth-quarter reserve adjustments. As of Dec 31, 2025, cash, cash equivalents and short-term investments totaled $414.1M (no debt), up $170.4M in 2025 (unaudited). Approximately 18% of 14,000 multiple-recurrence patients were on ARCALYST at year end; >4,150 prescribers have written ARCALYST prescriptions. Clinical milestones: KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. PT (5:15 p.m. ET). A live webcast will be available via the company's Investors website and a replay will be posted approximately 48 hours after the event.
Investors can access the webcast at www.kiniksa.com.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. GMT (9:30 a.m. ET). Management's presentation will be webcast live and accessible via the Investors section of Kiniksa's website at www.kiniksa.com. A replay will be posted on the company website approximately 48 hours after the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q3 2025 results and portfolio updates on October 28, 2025. ARCALYST net product revenue was $180.9M in Q3, a 61% year-over-year increase, leading Kiniksa to raise 2025 ARCALYST guidance to $670M–$675M (from $625M–$640M). The company reported net income of $18.4M in Q3 versus a net loss of $12.7M in Q3 2024. Cash, cash equivalents and short-term investments rose by $44.3M to $352.1M as of September 30, 2025, with no debt.
Pipeline news: FDA granted Orphan Drug Designation to KPL-387 for pericarditis; Phase 2 dose-finding data expected in H2 2026, then pivotal start. KPL-1161 remains in IND-enabling work.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report third quarter 2025 results and recent portfolio execution on Tuesday, October 28, 2025 at 8:30 a.m. ET. The company will host a conference call and live webcast accessible via the Investors & Media section of www.kiniksa.com.
Participants can register to join by telephone and will receive a confirmation email with dial-in details, a unique passcode, and registrant ID. A replay will be available on Kiniksa’s website approximately 48 hours after the event.
Kiniksa (Nasdaq: KNSA) announced that the U.S. FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, including recurrent pericarditis, on October 17, 2025.
KPL-387 is an independently developed monoclonal antibody that binds IL-1R1, inhibiting signaling of IL-1α and IL-1β. The company highlights potential dosing as a single monthly subcutaneous self-injection in a liquid formulation. Data from the Phase 2 dose-focusing portion of the Phase 2/3 recurrent pericarditis trial are expected in the second half of 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in two major investor conferences in September 2025. The company's management will engage in fireside chats at the Citi 2025 Biopharma Back to School Summit on September 3 at 9:00 a.m. ET and the 2025 Wells Fargo Healthcare Conference on September 4 at 9:30 a.m. ET.
Both presentations will be available via live webcast through Kiniksa's website investor section, with replays accessible within 48 hours after each event.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported strong Q2 2025 financial results, with ARCALYST net product revenue reaching $156.8 million, representing a 52% year-over-year growth. The company raised its 2025 ARCALYST revenue guidance to $625-640 million from $590-605 million.
Key highlights include net income of $17.8 million compared to a $3.9 million loss in Q2 2024, and a robust cash position of $307.8 million. ARCALYST's commercial success continues with over 3,475 prescribers and approximately 15% penetration of the target 14,000 multiple-recurrence patient population.
The company also announced progress in its pipeline, initiating the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, with Phase 2 data expected in 2H 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has scheduled its second quarter 2025 financial results conference call and webcast for Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time. The company will discuss its Q2 2025 financial performance and recent portfolio developments.
Investors can access the live webcast through the Investors & Media section on www.kiniksa.com. For telephone participation, interested parties must pre-register to receive dial-in details. A replay will be available on the company's website within 48 hours after the event.